Clinical Trial Update: Electroacupuncture Combined With Paclitaxel Protein-bound and PD-1 Antibody for Second-line Treatment of HER2 Negative, pMMR/MSS Advanced Gastric Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of electroacupuncture, paclitaxel protein-bound, and a PD-1 antibody as second-line therapy for HER2-negativ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)
• PD-1 antibody (PD-1 inhibitor)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Electroacupuncture Combined With Paclitaxel Protein-bound and PD-1 Antibody for Second-line Treatment of HER2 Negative, pMMR/MSS Advanced Gastric Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING